Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 7/20 | 0.47 |
| ▸ | RPS6KA3 | P51812 | 8/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
| ▸ | GCGR | P47871 | 1/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.37 |
| ▸ | FNTA | P49354 | 1/20 | 0.36 |
| ▸ | FNTB | P49356 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6718579 | 0.90 | KCNA5 (0.46) | SLC22A12RPS6KA3CYP11B2CYP11B1 | |
| SCHEMBL6723848 | 0.87 | RPS6KA3 (0.57) | SLC22A12RPS6KA3CYP11B2 | |
| SCHEMBL6725468 | 0.85 | RPS6KA3 (0.46) | SLC22A12RPS6KA3 | |
| SCHEMBL6721866 | 0.85 | RPS6KA3 (0.56) | SLC22A12RPS6KA3 | |
| SCHEMBL6729769 | 0.85 | RPS6KA3 (0.45) | SLC22A12RPS6KA3CYP11B2CYP11B1 | |
| SCHEMBL6725817 | 0.84 | SLC22A12 (0.43) | SLC22A12RPS6KA3CYP11B2CYP11B1 | |
| SCHEMBL6725357 | 0.84 | SLC22A12 (0.41) | SLC22A12RPS6KA3CYP11B2CYP11B1 | |
| SCHEMBL6723045 | 0.84 | RPS6KA3 (0.45) | RPS6KA3 | |
| SCHEMBL6723317 | 0.84 | RPS6KA3 (0.59) | SLC22A12RPS6KA3 | |
| SCHEMBL6719310 | 0.83 | RPS6KA3 (0.49) | SLC22A12RPS6KA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040092552-A1 | 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation | PHARMACIA CORPORATION | 2004-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092552-A1 | 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation | FPR2, PTGES2, FPR1 | SLC22A12 4098/4885RPS6KA3 972/4885CYP11B2 318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.